Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

Core Points - Novavax, Inc. will report its fourth quarter and full year 2024 financial results and operational highlights on February 27, 2025, at 8:30 a.m. ET [1] - The company specializes in protein-based vaccines and utilizes its proprietary Matrix-M™ adjuvant to enhance immune response [3] Conference Call Details - The conference call is scheduled for February 27, 2025, at 8:30 a.m. U.S. ET, with a registration URL provided for participants [1] - A replay of the call will be available starting at 11:30 a.m. U.S. ET on the same day until March 6, 2025 [2] Company Overview - Novavax is based in Gaithersburg, Maryland, and focuses on developing innovative vaccines for serious infectious diseases [3] - The company's portfolio includes a COVID-19 vaccine and candidates for COVID-19-Influenza Combination and stand-alone influenza vaccines [3] - Novavax's adjuvant is also part of the malaria vaccine developed by the University of Oxford and Serum Institute of India [3]